Watson Pharmaceuticals: Notice on receipt of approval letter for drug re-registration
Watson Pharmaceuticals: Announcement on the approval of licorice and plum tablets for registration in Singapore
Watson Pharmaceuticals: 2024 Semi-Annual Equity Distribution Implementation Notice
Watson Pharmaceuticals: 2024 Semi-Annual Results Online Briefing Investor Relations Activity Record Form
Chongqing Pharscin Pharmaceutical: Announcement Regarding Profit Distribution Plan for H1 2024.
Chongqing Pharscin Pharmaceutical: Notice of Online Performance Presentation for the First Half of 2024
Chongqing Pharscin Pharmaceutical: Announcement on the Action Plan for Double Improvement of Quality and Profit
Chongqing Pharscin Pharmaceutical: Regulations on information disclosure (August 2024)
Chongqing Pharscin Pharmaceutical: Announcement of the resolution of the Supervisory Board on the semi-annual report.
Chongqing Pharscin Pharmaceutical: Announcement of Board of Directors' resolution for semi-annual report.
Chongqing Pharscin Pharmaceutical: Summary of Half-Year Report in 2024.
Chongqing Pharscin Pharmaceutical: Financial Report for the first half of 2024.
Chongqing Pharscin Pharmaceutical: Half-year report for the year 2024.
Chongqing Pharscin Pharmaceutical: Summary table of non-operating funds utilization and other related funds flow for the first half of the year.
Chongqing Pharscin Pharmaceutical: Announcement regarding the receipt of pharmaceutical re-registration approval notice.
Chongqing Pharscin Pharmaceutical: Investor Relations Activity Record Form on July 24th, 2024
Chongqing Pharscin Pharmaceutical: Announcement Regarding Completing Domestic Production Pharmaceutical Filing for the Product.
Chongqing Pharscin Pharmaceutical: Announcement Regarding Completion of Business Registration Changes.
Chongqing Pharscin Pharmaceutical: Announcement regarding the company's pharmaceutical production license change and passing the GMP compliance inspection.
Chongqing Pharscin Pharmaceutical: Announcement regarding the receipt of approval notice for re-registration of active pharmaceutical ingredient.
No Data
No Data